'On standalone basis
Quarter ended September 2024 compared with Quarter ended September 2023.
Net sales (including other operating income) of Pfizer has increased 2.33% to Rs 588.59 crore. Operating profit margin has jumped from 31.75% to 32.15%, leading to 3.64% rise in operating profit to Rs 189.25 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 15.71% to 14.32%. Purchase of finished goods cost rose from 14.84% to 15.07%. Employee cost increased from 16.84% to 18.83%. Other expenses fell from 18.38% to 16.42%.
Other income up 19.41% to Rs 43.07 crore. PBIDT rose 6.24% to Rs 232.32 crore. Provision for interest fell 23.08% to Rs 2.1 crore. Loan funds declined from Rs 42.63 crore as of 30 September 2023 to Rs 36.94 crore as of 30 September 2024. Inventories rose to Rs 454.82 crore as of 30 September ...
Pleaselogin & subscribe to view the full report.
More Reports
-
-
Pricing pressures weighed on margins
-
-
|
|